The tweet was deleted by the author.
But we saved everything 🙂.
Moderna receives FDA approval for 2026-2027 vaccine formulas: Will MRNA hold $130.25 support?
Moderna said the U.S. Food and Drug Administration approved new 2026-2027 formulas of its Spikevax and mNEXSPIKE COVID-19 vaccines. The stock is down 3.9% on the day at $144.17.
MRNA price prediction
Current price:
$278.21
24.44
9.63%
Real-time Data
14:26
Daily range
254.81
280.32
280.32
Weekly range
222.01
267.11
267.11
Loading...
Highlights
- The FDA approved new 2026-2027 mRNA-based formulas of Moderna Spikevax and mNEXSPIKE targeting the JN.1-lineage XFG COVID-19 subvariant.
- Moderna stock is down 3.9% on the day at $144.17.
- Among 94 analysts, 15 rate Moderna stock a buy, 14 recommend selling, and the median price target is $45.
Moderna stated that the U.S. Food and Drug Administration has approved supplemental Biologics License Applications for the 2026-2027 formulas of Spikevax and mNEXSPIKE, both mRNA-based COVID-19 vaccines. The newly approved formulas include the JN.1-lineage XFG subvariant. The company operates in biotechnology and has a workforce of 4,700.
View post on X Loading...
Bullish structure holds as price gaps down but stays above key moving averages
The session opened with a gap down from the previous close of $150.01 to $144.83. Despite this decline, price remains above its MA-20, MA-50, and MA-200, maintaining a bullish daily structure. RSI at 68.5 is nearing overbought territory, which is an early sign the advance may be getting stretched. The nearest support sits at the weekly low of $130.25.
Odds strongly favor the upside as traders eye closes above $160.6
To gauge whether the regulatory event is being reflected in Moderna stock, traders should look for confirmation or rejection near key levels. The price gapped down from $150.01 to $144.83 at the open, showing a marked reaction at the outset of the session. Even so, over the next five trading days, there is a 74% probability of upside moves and a 26% probability of downside, with the expected range set between $130.59 and $157.74. A close above $160.6 would indicate buyers are pressing the advance, while a drop below $130.25 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Earlier, analysts noted that Moderna had entered a profit-taking phase following a substantial rally and that recent convertible financing introduced additional short-term risks. The FDA approval of updated vaccine formulas adds operational momentum, but with the current technical setup stretched, traders should closely monitor price behavior around the $130.25 support as a key indicator for potential trend shifts.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
